A Phase III Study to Evaluate the Effect of Balcinrenone/Dapagliflozin in Patients With CKD Stage 3b and 4 (BalanceD-CKD)
A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 2800 participants.
Also called NCT07624305
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 2,800 participants
- Sponsor
- Registry
-
NCT07624305 -
2026-526114-90-00
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- United States, Argentina, Austria, Brazil, Bulgaria, Canada, China, France, Germany, Greece, India, Italy, Japan, Malaysia, Mexico, Peru, Philippines, Poland, Romania, South Korea, Spain, Taiwan, Thailand, Türkiye, Ukraine, United Kingdom, Vietnam
- Registry status
- Recruiting
Technical summary
Registry record NCT07624305. Randomized; quadruple masking; primary purpose treatment. Start 2026-09-01 (actual); primary completion 2030-07-01 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Phase III Study to Evaluate the Effect of Balcinrenone/Dapagliflozin in Patients With CKD Stage 3b and 4 (BalanceD-CKD)
- Condition
- Renal Insufficiency, Chronic
- Intervention (Drug)
- Balcinrenone/dapagliflozin
- Intervention (Drug)
- Dapagliflozin
- Intervention (Drug)
- Placebo matching Dapagliflozin
- Intervention (Drug)
- Placebo matching balcinrenone/dapagliflozin
- Lead sponsor
- AstraZeneca
Record details
- Record id
cardio:ct-nct07624305- Content hash
5d9fa1316a5de506620958201e04c5d42b1930ddd49b86d411db9185c7e1f6bb